Trial Profile
A pivotal trial investigating combination of neratinib plus fulvestrant
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Neratinib (Primary)
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- 15 Dec 2015 New trial record
- 10 Dec 2015 According to a Puma Biotechnology media release, this trial is expected to start in 2016.